

1 **Establishment of a *Mycoplasma hyorhinis* challenge model in five-week-old piglets**

2

3 Dorottya Földi<sup>1,2</sup>, Zsófia Eszter Nagy<sup>1,2</sup>, Nikolett Belecz<sup>1,2</sup>, Levente Szereedi<sup>2,3</sup>, József Földi<sup>4</sup>,

4 Anna Kollár<sup>2,3</sup>, Miklós Tenk<sup>2,3</sup>, Zsuzsa Kreizinger<sup>1,2,5</sup>, Miklós Gyuranecz<sup>1,2,5,\*</sup>

5

6 <sup>1</sup>Veterinary Medical Research Institute, Budapest, Hungary

7 <sup>2</sup>National Laboratory of Infectious Animal Diseases, Antimicrobial Resistance, Veterinary  
8 Public Health and Food Chain Safety, Budapest, Hungary

9 <sup>3</sup>University of Veterinary Medicine, Budapest, Hungary

10 <sup>4</sup>Euvet Bt., Gödöllő, Hungary

11 <sup>5</sup>MolliScience Kft., Biatorbágy, Hungary

12

13 \*Corresponding author

14

15 E-mail addresses:

16 DF: foldi.dorottya@vmri.hu

17 ZEN: nagy.eszter.zsofia@vmri.hu

18 NB: belecz.nikolett@vmri.hu

19 LS: szereedi.levente@univet.hu

20 JF: euvet.bt@gmail.com

21 AK: kollar.anna@univet.hu

22 MT: tenk.miklos@univet.hu

23 ZK: kreizinger.zsuzsa@vmri.hu

24 MG: m.gyuranecz@gmail.com

25

26 **Summary**

27 *Mycoplasma hyorhinis* is an emerging swine pathogen bacterium with high prevalence  
28 worldwide. The main lesions caused are arthritis and polyserositis and the clinical manifestation  
29 of the disease may result in significant economic losses due to the decreased weight gain and  
30 enhanced medical costs.

31 Our aim was to compare two challenge routes to induce *M. hyorhinis* infection using the same  
32 clinical isolate. Five-week-old, Choice hybrid pigs were inoculated on two consecutive days by  
33 intravenous route (Group IV-IV) or by intravenous and intraperitoneal route (Group IV-IP).  
34 Mock infected animals were used as control (Control Group). After challenge, the clinical signs  
35 were recorded for 28 days, after which the animals were euthanized. Gross pathological and  
36 histopathological examinations, PCR detection, isolation and genotyping of the re-isolated  
37 *Mycoplasma* sp. and culture of bacteria other than *Mycoplasma* sp. were carried out. ELISA  
38 test was used to detect anti-*M. hyorhinis* immunoglobulins in the sera of all animals. Pericarditis  
39 and polyarthritis were observed in both challenge groups, however the serositis was more severe  
40 in Group IV-IV. Statistically significant differences were detected between the challenged  
41 groups and the control group regarding the average daily weight gain, pathological scores and  
42 ELISA titres. Additionally, histopathological scores in Group IV-IV differed significantly from  
43 the scores in the Control Group. All re-isolated strains were the same or a close genetic variant  
44 of the original challenge strain. Our results indicate that both challenge routes are suitable for  
45 modelling the disease. However, due to the more severe pathological lesions and the more  
46 natural-like route of infection in Group IV-IV, the two-dose intravenous challenge is  
47 recommended by the authors to induce serositis and arthritis associated with *M. hyorhinis*  
48 infection.

49

50 **Key words:** challenge, ELISA, infection, *Mesomycoplasma hyorhinis*, PCR, pig

51

52 **Introduction**

53 *Mycoplasma hyorhinis* is an emerging pathogenic bacterium of swine, distributed worldwide  
54 with an estimated prevalence of 50-70% in the herds (Pieters & Maes, 2019; Roos et al., 2019).  
55 *M. hyorhinis* colonises the upper respiratory tract and tonsil of sows, which are asymptomatic  
56 carriers of the bacterium. Piglets get infected directly from the nasal secretions of sows, and  
57 later from each other, especially after weaning (Clavijo et al., 2017). Clinical signs usually  
58 appear between three to ten weeks of age. Although the susceptibility to the infection decreases  
59 after this age, pigs can get infected even up to 16 weeks of age (Martinson et al., 2017). The  
60 pathomechanism of systemic spread is still not fully understood. Predisposing factors, such as  
61 inadequate housing conditions or weaning and decreasing maternal antibodies around three  
62 weeks of age can all contribute to the disease (Clavijo et al., 2019).

63 The first clinical signs appear on the third to tenth days after exposure and include fever and  
64 lethargy (Gomes Neto et al., 2012). Later coughing, laboured breathing and dyspnoea can  
65 appear due to serofibrinous pleuritis, pericarditis and peritonitis. Additionally, arthritis with  
66 swollen joints and lameness can be observed in pigs (Barden & Decker, 1971). Rarely, *M.*  
67 *hyorhinis* infection can cause otitis (Morita et al., 1995), conjunctivitis (Resende et al., 2019)  
68 and meningitis (Bünger et al., 2020). Affected pigs show growth retardation which can be  
69 evident even five months after infection (Barden & Decker, 1971). As a secondary pathogen  
70 *M. hyorhinis* can aggravate the clinical signs of other infections like porcine circovirus 2  
71 associated diseases, porcine respiratory disease complex and enzootic pneumonia (Pieters &  
72 Maes, 2019). Decreased weight gain and cost of medical treatments result in significant  
73 economic losses. As no commercial vaccine is available in Europe, prevention mainly relies on  
74 decreasing predisposing factors, however metaphylactic antibiotic treatment is often required.  
75 There are some *M. hyorhinis* challenge models in the literature suggesting different inoculation  
76 routes. Not all of these models are suitable for vaccine efficacy studies as with some of the

77 suggested challenge routes not all typical lesions can be induced (Martinson, Minion, et al.,  
78 2018).

79 Our aim was to compare the effects of experimental infections of two distinct inoculation routes  
80 with the same virulent *M. hyorhinis* strain by studying the colonisation of the bacteria, clinical  
81 signs, immune response and macroscopic and microscopic alterations. Accordingly, the  
82 examinations also aimed to establish a challenge model for future vaccine efficacy studies.

83

84 **Materials and methods**

85 *Challenge material*

86 The *M. hyorhinis* isolate used during this study was isolated from the pericardium of an affected  
87 pig originated from Hungary in 2016. The initial isolation was carried out using the filter  
88 cloning technique in Mycoplasma Experience Medium (Mycoplasma Experience Ltd.,  
89 Bletchingley, UK). The challenge material was prepared freshly for each challenge day by  
90 inoculating the isolate 48 hours prior challenge and incubating at 37°C. The copy number  
91 determination was carried out on the day of the challenge. The number of colour changing units  
92 (CCU/ml) were calculated by plate micro-dilution from the highest dilution showing colour  
93 change (red to yellow shift) (Hannan, 2000).

94

95 *Experimental animals*

96 Sixteen, four-week-old Choice hybrid piglets were transported to the animal house of the  
97 Veterinary Medical Research Institute six days prior infection. The animals were obtained from  
98 a farm with low *M. hyorhinis* prevalence and high health status (free from: brucellosis,  
99 leptospirosis, Aujeszky's disease, porcine reproductive and respiratory syndrome, swine  
100 dysentery, atrophic rhinitis, *Actinobacillus pleuropneumoniae*, *Mycoplasma hyopneumoniae*,

101 lice and mange). The *M. hyorhinis* free status of the piglets were checked before challenge by  
102 real-time PCR testing and *Mycoplasma* culture of nasal swabs.

103 Upon arrival, the animals were weighed and randomly divided into three groups with similar  
104 average weight. The groups were housed in separate pens, feed and water were provided *ad*  
105 *libitum*. The experiment was approved by the National Scientific Ethical Committee on Animal  
106 Experimentation under reference number: PE/EA/746-7/2021.

107

108 *Challenge routes*

109 Group IV-IV (n=6) was inoculated by intravenous (IV) route on days 0 and 1 (D0, D1) with 10  
110 ml  $10^6$  CCU/ml challenge material. Group IV-IP (n=6) was challenged IV on D0 with 10 ml  
111  $10^6$  CCU/ml challenge material and intraperitoneal (IP) route on D1 with 20 ml  $10^6$  CCU/ml  
112 challenge material. Total challenge dose was  $2 \times 10^7$  CCU/pig and  $3 \times 10^7$  CCU/pig in Group  
113 IV-IV and IV-IP, respectively. The controls (n=4) were inoculated by IV route on D0. Two of  
114 these animals were inoculated by IV route and the remaining two pigs by IP route on D1.  
115 Animals in the Control Group received only sterile liquid media in the same volume as the  
116 challenged groups.

117

118 *Clinical observation*

119 The animals were observed daily from D0 until the end of the study at D28. Clinical signs of  
120 arthritis (swollen joints, lameness) and respiratory disease (coughing or laboured breath) were  
121 recorded. Body temperatures were measured daily from D-2. Body weight measurement, blood  
122 and nasal swab sampling were carried out twice a week. Schedule of events are summarized in  
123 Table 1. Average daily weight gain (ADWG) was calculated by subtracting the weight  
124 measured at D-6 from the weight measured at D27 and dividing it by the number of days past  
125 (n=33).

126 **Table 1: Schedule of events, challenge routes and doses.**

127 <sup>†</sup>IV-intravenous, IP-intraperitoneal, CCU-colour changing unit

128

Time	Event <sup>†</sup>	Challenge dose <sup>†</sup>
D-6	Arrival of 16 four-week-old piglets Body weight measurement  Blood sampling Collection of nasal swabs for PCR and <i>Mycoplasma</i> isolation Body temperature measurement	
D-1	Body temperature measurement	
D0	IV challenge of all groups  IV challenge of Group IV-IV and two animals from Control Group	10 ml 10 <sup>6</sup> CCU/ml challenge material (Groups IV-IV and IV-IP) or 10 ml sterile broth (Control Group)
D1	IP challenge of Group IV-IP and two animals from Control Group 3  Daily body temperature measurement and clinical observations	IV: 10 ml 10 <sup>6</sup> CCU/ml challenge material (Group IV-IV) or 10 ml sterile broth (Control Group)
D0-D27	Twice a week body weight measurement Collection of nasal swabs for PCR and <i>Mycoplasma</i> isolation Blood sampling Euthanasia	IP: 20 ml 10 <sup>6</sup> CCU/ml challenge material (Group IV-IP) or 20 ml sterile broth (Control Group)
D28	Pathological examination Sample collection for PCR, histopathology and bacteriology	

129

130

131

132 *Isolation, DNA extraction and PCR*

133 Nasal swabs for *Mycoplasma* isolation and PCR were taken twice a week from all animals  
134 throughout the study. Separate swab samples for *Mycoplasma* isolation and PCR were collected  
135 during necropsy as well (see below). For *Mycoplasma* isolation swabs were cut into  
136 *Mycoplasma* liquid media (Mycoplasma Experience Ltd.), washed then filtered by 0.45 µm  
137 pore size filters and incubated at 37°C until colour change.

138 DNA extraction from the swabs and colour changed broths were performed by ReliaPrep gDNA  
139 Tissue Miniprep System (Promega Inc., Madison, USA) according to the manufacturers'  
140 instructions. For the *M. hyorhinis* species specific real-time PCR, previously published  
141 (Resende et al., 2019) primers targeting the 16S rRNA gene were optimized. Primer and probe  
142 sequences were the following: Forward primer 5'- CGT ACC TAA CCT ACC TTT AAG -3',  
143 Reverse primer 5'- TAA TGT TCC GCA CCC C -3', Probe 5'- FAM-CCG GAT ATA GTT  
144 ATT TAT CGC ATG ATG AG-BHQ -3'. The PCR was performed using a Bio-Rad C1000  
145 Touch™ Thermal Cycler, CFX96™ Real-Time System (Bio-Rad Laboratories Inc., USA). The  
146 PCR master mix consisted of 6 µl 2× qPCR BIO Probe Mix No-ROX (PCR Biosystems Ltd.,  
147 UK), 0.4 µl of each primer (10 µM), 0.2 µl probe and 2 µl DNA in the final volume of 12 µl.  
148 PCR conditions were the following 95°C for two minutes, 45 cycles of 95°C for 5 seconds and  
149 60°C for 20 seconds. In order to test the sensitivity of the developed assays, tenfold dilutions  
150 of the type strain (NCTC 10130) were used in the range of 10<sup>6</sup>-10<sup>0</sup> copy number/µl. Template  
151 copy number was calculated with the help of an online tool (<http://cels.uri.edu/gsc/cndna.html>)  
152 by measuring the concentration of DNA of pure *M. hyorhinis* culture by Nanodrop 2000  
153 Spectrophotometer (Thermo Fisher Scientific Inc., USA). The lowest DNA concentration  
154 giving specific signal was considered the detection limit of the assay. The specificity was tested  
155 by including *M. hyopneumoniae*, *M. hyosynoviae* and *M. flocculare* in the analyses.

156 Necropsy samples were also tested for the presence of *M. hyopneumoniae* (Wu et al., 2019) and  
157 *M. hyosynoviae* (Martinson, Minion, et al., 2018) by PCR. *M. hyorhinis* positive isolates were  
158 genetically characterized by multi-locus sequence typing (MLST: costly and robust genotyping  
159 system) and multiple-locus variable-number tandem-repeat analysis (MLVA: fast and cheap  
160 genotyping system with high-resolution) by previously published assays (Földi et al., 2020).

161

162 *Gross pathological examination*

163 Joints of carpus, elbow, tarsus and stifle on both sides were opened and examined for the signs  
164 of arthritis. The thoracic and abdominal cavity (pleura, pericardium, peritoneum) were checked  
165 for serositis. Body condition, skin, subcutaneous tissues, musculoskeletal system, eyes and  
166 conjunctiva, nasal, and oral cavity, trachea, lungs, heart, lymph nodes, gastrointestinal system,  
167 liver, spleen, kidney and brain were also checked for lesions. Scoring system of the gross  
168 pathological examination is detailed in Supplementary table 1. Lesions of joints and serosa were  
169 scored to reflect severity based on previously described criteria (Martinson, Zoghby, et al.,  
170 2018). Total scores were calculated by summarizing all organ scores.

171 Swab samples for bacterial culture, *M. hyorhinis* isolation and PCR were taken from the  
172 conjunctiva, lung, serosa, the four examined joints and brain. Joints on both sides were sampled  
173 with the same swab.

174

175 *Histological examination*

176 Samples for histopathology were collected from conjunctiva, choana, tonsilla, trachea, lungs (7  
177 lobes), pericardium, heart, mediastinal and mesenterial lymph nodes, liver, spleen, kidney,  
178 joints and brain (cerebrum, cerebellum, brain stem). Tissue samples were fixed in 10%  
179 formaldehyde, embedded in paraffin then 4 µm thick sections were cut and stained with  
180 haematoxylin and eosin (H&E) and examined by light microscope. Data about the scoring

181 system of *M. hyorhinis* infected tissue lesions are scarce in the literature. Given the limited  
182 number of examined animals in the present study, the establishment of a general scoring system  
183 was not possible either. Therefore, lesions were categorized based on the comparison of the  
184 severity of the histopathological changes to each other, and scores were assigned as follows: 0-  
185 no lesion, 1-mild lesion, 2-moderate lesion, 3- severe lesion in the given organ.

186

187 *Bacteriology*

188 Presence of bacterial pathogens other than *Mycoplasma* sp. were tested by culturing the  
189 necropsy samples on Columbia sheep blood agars (Biolab Inc., Hungary) and sheep blood agars  
190 supplemented with nicotinamide adenine dinucleotide (Sigma-Aldrich Co., USA) at the final  
191 concentration of 20 µg/ml. The agar plates were incubated at the presence of 5% CO<sub>2</sub> at 37°C  
192 for 48 hours.

193

194 *Serology*

195 Sera were tested in duplicates by an in-house ELISA, using an antigen prepared according to  
196 the sarcosyl assay previously described for *M. gallisepticum* (Stipkovits et al., 1993). Briefly,  
197 to prepare the antigen, six clinical isolates of *M. hyorhinis* were propagated (Supplementary  
198 table 2). After colour change the isolates were mixed, washed and treated with 0.5% sarcosyl.  
199 Protein content of the antigen was determined with Coomassie (Bradford) Protein assay kit  
200 (Thermo Fisher Scientific Inc.) according to the manufacturer's instructions.

201 96-well ELISA plates were coated with the antigen diluted to the concentration of 1.25 µg/ml  
202 in phosphate buffered saline (PBS, pH 7.4). After blocking with 1% gelatine from cold water  
203 fish skin (Sigma-Aldrich Co.) each well was incubated with serum sample diluted to 1:100 in  
204 PBS, followed by a horseradish peroxidase conjugated rabbit anti-swine immunoglobulin  
205 (Dako A/S, Denmark) diluted to 0.125 µg/ml in PBS. The reaction was visualized with

206 tetramethylbenzidine (TMB, Diavet Ltd., Hungary) substrate and the optical density of the  
207 solution was measured at 450 nm using a Multiscan FC reader (Thermo Fisher Scientific Inc.).  
208 Blood samples were centrifuged after collection and the sera were kept at -70°C. Each serum  
209 sample were thawed only once. Each plate contained a negative control (mix of the sera of each  
210 Control animal taken at D28 from this study) a positive control (mix of the sera of each animal  
211 in Group IV-IV taken at D28 from this study) and a background control, where PBS was  
212 measured instead of the serum sample. The mean OD value of the background control was  
213 subtracted from the mean OD values of the samples and the controls (Terato et al., 2017). The  
214 assay was considered valid if the negative to positive ratio of corrected OD values were under  
215 40%. The sample to positive ratios (S/P%) were calculated and the sample was considered  
216 positive when S/P%>40% (Merodio et al., 2021).

217

#### 218 *Statistical analyses*

219 Statistical analyses were accomplished with R programme (R Core Team, 2021). To compare  
220 the effect of the different challenge routes statistical analysis of the ADWG, pathological scores  
221 (separately for the joints, serosa of pericardium, pleura and peritoneum and summary of scores),  
222 histopathological scores (separately for the joints, serosa of pericardium, pleura and peritoneum  
223 and summary of scores) and ELISA results from the last sampling were performed. In case of  
224 the pathological and histopathological scores first a Kruskal-Wallis non-parametric ANOVA  
225 test was carried out to determine whether the difference among the medians of the three study  
226 groups are statistically significant or not. If the results of the Kruskal-Wallis test were  
227 significant a Dunn's test was performed to determine exactly which groups are different by  
228 making pairwise comparisons between each group. Since multiple groups were considered at  
229 the same time, p-values were adjusted for multiple comparisons by Bonferroni method. In case  
230 of the ADWG and the ELISA results instead of the non-parametric test a one-way ANOVA

231 followed by Tukey multiple comparisons of means was performed after the normal distribution  
232 of the data was tested by Shapiro-Wilk normality test.

233

## 234 **Results**

### 235 *Clinical observations*


236 No clinical alterations were detected in the Control Group throughout the study. No body  
237 temperature higher than 40.3°C was recorded during the study. One pig in Group IV-IP had  
238 body temperatures higher than 40°C on three consecutive days (D4-6, Supplementary table 3).

239 No respiratory signs were recorded in the challenge groups.

240 Swollen joints were detected as early as D6 in Group IV-IP and D8 in Group IV-IV. Typically,  
241 the first swollen joint was one of the tarsal joints. By D15 all pigs in Group IV-IP had at least  
242 one swollen joint, 3/6 pigs had two swollen tarsi and in one animal joints of the front legs were  
243 also affected. In Group IV-IV swollen tarsal joint was observed in 4/6 pigs (one side only) and  
244 in one animal both tarsi were affected, while no swollen joints were detected in one pig  
245 (Supplementary table 4).

246 Weight gain dynamics of the different groups are shown in Figure 1 and detailed in  
247 Supplementary table 5. Average starting weight of the groups were 10.5 kg (SD 1.2), 10.3 kg  
248 (SD 1.2) and 10.3 kg (SD 1.1) in Group IV-IV, IV-IP and Control while at the end of the study  
249 average body weight of the groups were 18.0 kg, 16.0 kg and 22.0 kg respectively. Mean  
250 ADWG was 223 g, 170 g and 350 g in Group IV-IV, IV-IP and Control Group. Significant  
251 differences in ADWG were detected between Groups Control and IV-IV ( $p=0.05$ ) and Groups  
252 Control and IV-IP ( $p<0.01$ ; Supplementary data 1).

253



254

255 **Figure 1: Average weight of the study groups at each sampling point.**

256 The arrow marks the first day of the challenge.

257

258 *Mycoplasma isolation, PCR and bacteriology*

259 Sensitivity of the reaction with the optimized primers were  $10^1$  copies/reaction, no cross  
260 reactions were detected for *M. hyopneumoniae*, *M. hyosynoviae* and *M. flocculare*.

261 Nasal swabs of all animals were negative for *M. hyorhinis* by PCR and isolation at the beginning  
262 of the study (D-2). After the inoculation of the pigs one sample from each challenged group  
263 was positive by isolation which were positive also by PCR either at same time or at different  
264 sampling times. These animals remained PCR positive for two-four consecutive sampling  
265 points. Further two animals in Group IV-IV and one animal in Group IV-IP were PCR positive  
266 as well at one sampling point. All nasal samples of Control Group were negative by PCR and  
267 isolation for *M. hyorhinis* throughout the study (Supplementary table 6).

268 Samples collected from the conjunctiva and meninx during necropsy were negative for the  
269 tested mycoplasmas in all animals, while one lung sample in Group IV-IV was positive for *M.*  
270 *hyorhinis* by PCR. Three samples from different serosa (pleura, pericardium, peritoneum) were

271 positive by PCR as well in Group IV-IV. High number of joint samples were positive by PCR  
272 in both challenged groups. In Group IV-IV 2/6 stifle, 4/6 elbow, 5/6 tarsus and 4/6 carpus  
273 samples were positive for *M. hyorhinis* by PCR. While in Group IV-IP 2/6 stifle, 4/6 elbow, 4/6  
274 tarsus and 1/6 carpus samples were positive. All samples from Control Group were negative for  
275 *M. hyorhinis* (Supplementary table 7). *M. hyopneumoniae* or *M. hyosynoviae* were not detected  
276 in any samples collected during necropsy.

277 During the challenge study two nasal isolates and isolates from six necropsy samples (tarsal,  
278 carpal, elbow and stifle joints) were collected and their genotypes were first determined by  
279 MLVA. Two re-isolates in Group IV-IP differed from the challenge strain on one allele  
280 (MHR444; Supplementary table 8). They were microvariants due to within host evolution. The  
281 sequence types of these two isolates, two other isolates from the same animals and one isolate  
282 from Group IV-IV were also determined by MLST. All the re-isolated strains showed the same  
283 sequence type (ST) with MLST as the challenge strain (Supplementary data 2). MLST and  
284 MLVA trees are shown in Supplementary figure 1.

285 None of the cultures of the necropsy samples showed growth of pathogenic bacteria that could  
286 also be associated with the lesions, other than *M. hyorhinis*.

287

#### 288 *Gross pathological examination*


289 Arthritis of at least one joint was observed in all pigs in the challenge groups. Mild to severe  
290 arthritis was found in all joints examined in one pig and in three joints examined in another pig  
291 in Group IV-IV. A single joint was affected in the remaining four animals in this group. Mild  
292 to severe arthritis was found in three, two or one joints of two-two pigs in Group IV-IP. The  
293 arthritis manifested as serous or purulent inflammation (Figure 2A) and was detected most often  
294 in the tarsus (8/12) followed by elbow (6/12), stifle (5/12) and the carpus (4/12) on one or on  
295 both sides. In addition to arthritis, erosions in the cartilage were evident in the tarsal joint of

296 two animals in Group IV-IP, which indicates a prolonged time of inflammation of the joint  
297 (Figure 2B).

298 Diffuse, severe, chronic pericarditis presenting large amount of connective tissue was detected  
299 in two animals in both groups (Figure 2C). Additionally, mild or moderate chronic pleuritis  
300 presenting filaments of connective tissues were detected in two animals (Figure 2D) and mild  
301 chronic peritonitis presenting filaments of connective tissues occurred in one other animal in  
302 Group IV-IV.

303 Macroscopic scores of lesions in the affected organs are demonstrated in Figure 3. No gross  
304 pathological alterations were found in the remaining organs examined. No gross pathological  
305 lesions were detected in any examined organs in the Control Group. Body condition in all  
306 groups was normal. Detailed pathological scores are given in Supplementary table 1.

307 Significant differences in pathological scores were detected when scores of joint lesions and  
308 total scores of groups were compared: pathological scores in both challenge group differed  
309 significantly from the Control Group ( $p=0.03$  and  $p=0.02$  regarding joint lesions,  $p=0.02$  and  
310  $p=0.03$  regarding total scores for Group IV-IV-Control and Group IV-IP-Control, respectively),  
311 but not from each other in both cases. No significant difference was found when scores of serosa  
312 lesions were compared (Supplementary data 1).



313


314 **Figure 2: Typical lesions of *Mycoplasma hyorhinis* infection.**

315 A-Joint with excess synovial fluid. B-Cartilage erosion. C-Serofibrinous pericarditis. D-

316 Serofibrinous pleuritis.

317

318



319

320 **Figure 3: Scores of macroscopic lesions of the affected organs of the study groups.**

321 Organs were scored between 0-2 based on the severity of the lesion, except for the heart where  
322 score 1 was given in case of any lesion (Supplementary table 1). In the charts white indicates  
323 the number of animals with score 0, light grey indicates the number of animals with score 1 and  
324 black indicates the number of animals with score 2. The number of animals in each group is  
325 indicated on the Y-axis: the challenge groups consisted of six animals, while the control group  
326 involved four animals.


327

328 *Histological examination*

329 The results of the histological examination are summarised in Supplementary table 9. The main  
330 alterations were detected in the joints and in the serosa of parenchymal organs in the thoracic  
331 and peritoneal cavity. Arthritis was found in 6/6 pigs in Group IV-IV and 4/6 pigs in Group IV-  
332 IP. Mild to severe lympho-histiocytic inflammation associated with the formation of lymphoid  
333 follicle around blood vessels were detected in four animals in both Groups IV-IV and IV-IP,  
334 and the same changes with the presence of multinucleated giant cells were found in two infected  
335 animals in Group IV-IV (Figure 4A). Alterations in the pleura were present in 3/6 and 4/6

336 infected pigs in Groups IV-IV and IV-IP, respectively. Filamentous pleural projections  
337 consisting of connective tissue with serous-purulent inflammation and multinucleated giant  
338 cells were found in one animal in Group IV-IV (arthritis with multinucleated giant cells was  
339 also detected in the latter pig). Diffuse thickening of the pleura and filamentous pleural  
340 projections consisting of connective tissue with moderate serous-purulent inflammation were  
341 evident in 1/6 animals in Group IV-IV, while filamentous pleural projections of connective  
342 tissue without thickening of the pleura was detected in one animal (Figure 4B). Also diffuse  
343 thickening of the pleura with filamentous pleural projections consisting of connective tissue  
344 with lympho-histiocytic inflammation were evident in three animals in Group IV-IP while in  
345 this group one animal only presented diffuse thickening of the pleura without inflammation  
346 (Figure 4B). The epicardium and pericardium were affected in 3/6 and 2/6 animals in Groups  
347 IV-IV and IV-IP, respectively. Diffuse thickening of the pericardium, filamentous projections  
348 consisting of connective tissue on the pericardium and serous purulent inflammation were  
349 evident in one pig in both groups, and severe proliferation of connective tissue associated with  
350 adhesion of the epi- and pericardium were detected in two and one pigs in Groups IV-IV and  
351 IV-IP, respectively (Figure 4B). Alterations of the peritoneum was found in 1/6 infected pig in  
352 both groups. Filamentous projections consisting of connective tissue were detected on the  
353 serosa of spleen and liver of the animal in Group IV-IV, and on the serosa of the spleen of the  
354 pig in Group IV-IP. Additionally, lympho-histiocytic purulent conjunctivitis was found in two  
355 cases (one animal in both infected groups), and serous-purulent rhinitis in one case in Group  
356 IV-IV. No lesions were detected in the other organs.

357 Scores of histological lesions of affected organs are shown in Figure 5. Based on the statistical  
358 analysis, scores of joints and total score differed significantly between groups. In both cases  
359 significant differences were detected between Group IV-IV and Control ( $p=0.04$  regarding joint  
360 lesions,  $p=0.04$  regarding total score; Supplementary data 1).




361

362 **Figure 4: Typical histopathological changes in *Mycoplasma hyorhinis* infected piglets.**

363 A: Joint synovial membrane: Severe lympho-histiocytic inflammation associated with the  
364 formation of lymphoid follicle around blood vessels, H&E, 40×. A1: Perivascular follicle,  
365 H&E, 400×. B: Lung: Filamentous pleural projections consisting of connective tissue and  
366 serous-purulent inflammation. B1: Joint synovial membrane: Multinucleated giant cell is  
367 associated with lympho-histiocytic inflammation, H&E, 400×. B2: Pericardium: Severe  
368 proliferation of connective tissue associated with adhesion of the epi- and pericardium, H&E,  
369 40×.

370

371



372

373 **Figure 5: Scores of histopathologic lesions of the affected organs in the study groups.**


374 Organs were scored between 0-3 based on the severity of the lesion. In the charts white indicates  
375 the number of animals with score 0 (no lesion), light grey indicates the number of animals with  
376 score 1 (mild lesions), dark grey indicates the number of animals with score 2 (moderate  
377 lesions) and black indicates the number of animals with score 3 (severe lesions). The number  
378 of animals in each group is indicated on the Y-axis: the challenge groups consisted of six  
379 animals, while the control group involved four animals.

380

381 *Serology*

382 All animals were serologically negative to *M. hyorhinis* at the beginning of the study. The  
383 positive serological response appeared in both challenge groups on D5, SP% of 1/6 pigs in  
384 Group IV-IV and 2/6 pigs in Group IV-IP was higher than 40%. By D28 all challenged animals  
385 were ELISA positive. However, one animal in Group IV-IP, presented positive serological  
386 response just at the last sampling point (Supplementary table 10). Mean S/P% of the groups  
387 throughout the study are demonstrated in Figure 6. Significant differences in S/P% of D28 were  
388 detected between Control and Group IV-IV ( $p<0.01$ ) and Control and Group IV-IP ( $p<0.01$ ;  
389 Supplementary data 1). Animals from Control Group remained negative throughout the study.

390



391

392 **Figure 6: Mean sample-to-positive ratios (S/P%) of the blood samples during the study.**

393 The arrow marks the first day of the challenge.

394

395 **Discussion**

396 Based on available literature data, the single dose intranasal or intratracheal inoculation with  
397 *M. hyorhinis* is not suitable to establish a proper challenge model as these routes usually only  
398 able to induce one aspect of the infection, mostly polyserositis and lung lesions with little or no  
399 serological conversion after infection (Fourour et al., 2019; Gomes Neto, 2014; Lee et al., 2018;  
400 Lin et al., 2006; Wei et al., 2020). Similarly, intranasal inoculation combined with tonsillar  
401 swabbing resulted in low serological conversion with no clinical signs or macroscopic lesions  
402 (Merodio et al., 2021). Time of challenge should not have an impact on the results of previous  
403 experiments as all studies used pigs at a receptive age (infected mostly at six weeks of age  
404 (Fourour et al., 2019; Gomes Neto, 2014; Lee et al., 2018; Lin et al., 2006; Merodio et al.,  
405 2021), or at ten weeks of age (Wei et al., 2020). Our study plan was based on the work of  
406 Martinson, Minion, et al. (2018) where one-dose intranasal, intravenous and intraperitoneal  
407 inoculations were compared to two- or three-dose inoculations with combined challenge routes  
408 in seven-week-old animals. The results of this study also confirmed that a single dose challenge  
409 is not sufficient to induce all typical lesions, with the mildest clinical signs observed in the  
410 intranasally infected group. On the other hand, in the intravenously infected group the rate of  
411 pigs with pericarditis and pleuritis were similar to or higher than in the groups with combined  
412 challenge routes. The authors suggested the combination of intravenous, intraperitoneal and  
413 intranasal routes on three consecutive days to induce both polyserositis and polyarthritis  
414 (Martinson, Minion, et al., 2018; Wang et al., 2022).  
415 In the present study two challenge routes were compared by using the same virulent clinical  
416 isolate. The double dose IV challenge (which was not mentioned in previous publications)  
417 produced equal involvement of joints as the mix of IV-IP route (arthritis of at least one joint  
418 was detected in 6/6 animals in both groups), which exceeded the rate of animals affected with  
419 arthritis in the previous study (single dose IV challenge from Martinson's work resulted arthritis  
420 in only 1/10 animal). It should be mentioned though, that with the combination of intravenous

421 and intraperitoneal infection (Group IV-IP) clinical signs of arthritis like swollen joint and  
422 lameness appeared earlier and were more pronounced. On the other hand, in the group which  
423 was challenged by intravenous route on two consecutive days (Group IV-IV) more organs were  
424 affected by serositis than in the Group IV-IP. During necropsy, all lesions appeared chronic in  
425 both groups, therefore the reduction of the length of the study is suggested.

426 Although the natural route of infection is not yet fully understood, the results of the challenge  
427 models using intravenous route indicate that systemic spread of *M. hyorhinis* might happen  
428 through the circulatory or lymphatic system (Martinson, Minion, et al., 2018). This theory is  
429 further supported by the results of our study. Both of the applied challenge routes included  
430 intravenous infection, and accordingly systemic spread of *M. hyorhinis* was obtained in both  
431 cases. Furthermore, despite inoculating directly the peritoneum in Group IV-IP, peritonitis  
432 could be induced only by the double intravenous route, and overall the observed serositis was  
433 more pronounced in Group IV-IV. Nevertheless, as with both challenge methods the main  
434 lesions of *M. hyorhinis* infection were induced, both models can be recommended for the future  
435 studying of *M. hyorhinis* infection or for vaccine efficacy studies. Considering the hypothesis  
436 of the natural spread of the pathogen via the circulatory or lymphatic system and the more  
437 severe pathological lesions in Group IV-IV, two-dose intravenous challenge is recommended  
438 by the authors.

439

#### 440 **Data availability**

441 All data is available in the supplementary tables or supplementary data.

442

#### 443 **Ethics Statement**

444 The authors confirm that the ethical policies of the journal, as noted on the journal's guidelines  
445 page, have been adhered to and the appropriate ethical review committee approval has been

446 received. Regulations of the Hungarian Government on the use of laboratory animals were  
447 followed and our study was approved by the National Scientific Ethical Committee on Animal  
448 Experimentation under reference number: PE/EA/746-7/2021.

449

450 **Conflict of interest statement**

451 The authors have no conflict of interest to declare.

452

453 **Funding information**

454 This work was supported by the Momentum (Lendület) programme (LP2022-6/2022) of the  
455 Hungarian Academy of Sciences and the Project no. RRF-2.3.1-21-2022-00001 which has been  
456 implemented with the support provided by the Recovery and Resilience Facility (RRF),  
457 financed under the National Recovery Fund budget estimate, RRF-2.3.1-21 funding scheme.  
458 DF was supported by the New National Excellence program (ÚNKP-21-3) and the Doctoral  
459 Student Scholarship Program of the Co-operative Doctoral Program (KDP-2020) of the  
460 Ministry of Innovation and Technology. The funders had no role in study design, data collection  
461 and interpretation or the decision to submit the work for publication.

462

463 **Acknowledgements**

464 The authors are thankful for Balázs Lajos for his help providing the animals meeting the study  
465 criteria.

466

467 **References**

468 Barden, J. A., & Decker, J. L. (1971). *Mycoplasma hyorhinis* Swine Arthritis. I. Clinical and  
469 Microbiologic Features. *Arthritis & Rheumatism*, 14, 193–201.

470 <https://doi.org/10.1002/art.1780140202>

471 Bünger, M., Brunthaler, R., Unterweger, C., Loncaric, I., Dippel, M., Ruczizka, U., ...

472 Spergser, J. (2020). *Mycoplasma hyorhinis* as a possible cause of fibrinopurulent

473 meningitis in pigs? - A case series. *Porcine Health Management*, 6, 38.

474 <https://doi.org/10.1186/s40813-020-00178-8>

475 Clavijo, M. J., Murray, D., Oliveira, S., & Rovira, A. (2017). Infection dynamics of

476 *Mycoplasma hyorhinis* in three commercial pig populations. *Veterinary Record*, 181,

477 68–68. <https://doi.org/10.1136/vr.104064>

478 Clavijo, M. J., Davies, P., Morrison, R., Bruner, L., Olson, S., Rosey, E., & Rovira, A. (2019).

479 Temporal patterns of colonization and infection with *Mycoplasma hyorhinis* in two

480 swine production systems in the USA. *Veterinary Microbiology*, 234, 110–118.

481 <https://doi.org/10.1016/j.vetmic.2019.05.021>

482 Földi, D., Bekő, K., Felde, O., Kreizinger, Z., Kovács, Á. B., Tóth, F., ... Gyuranecz, M.

483 (2020). Genotyping *Mycoplasma hyorhinis* by multi-locus sequence typing and

484 multiple-locus variable-number tandem-repeat analysis. *Veterinary Microbiology*, 249,

485 108836. <https://doi.org/10.1016/j.vetmic.2020.108836>

486 Fourour, S., Tocqueville, V., Paboeuf, F., Lediguerher, G., Morin, N., Kempf, I., & Marois-

487 Créhan, C. (2019). Pathogenicity study of *Mycoplasma hyorhinis* and *M. flocculare* in

488 specific-pathogen-free pigs pre-infected with *M. hyopneumoniae*. *Veterinary*

489 *Microbiology*, 232, 50–57. <https://doi.org/10.1016/j.vetmic.2019.04.010>

490 Gomes Neto, J. C., Gauger, P. C., Strait, E. L., Boyes, N., Madson, M. & Schwartz, K. J.

491 (2012). Mycoplasma-associated arthritis: Critical points for diagnosis. *J Swine Health*

492 *Prod*, 20, 82-86.

493 Gomes Neto, J. C., Strait, E. L., Raymond, M., Ramirez, A. & Minion, F. C. (2014). Antibody

494 responses of swine following infection with *Mycoplasma hyopneumoniae*, *M.*

495 *hyorhinis*, *M. hyosynoviae* and *M. flocculare*. *Veterinary Microbiology*, 174, 163-171.

496 <http://dx.doi.org/10.1016/j.vetmic.2014.08.008>

497 Hannan, P. C. T. (2000). Guidelines and recommendations for antimicrobial minimum

498 inhibitory concentration (MIC) testing against veterinary mycoplasma species.

499 *Veterinary Research*, 31, 373–395. <https://doi.org/10.1051/vetres:2000100>

500 Kumar, S., Stecher, G., Li, M., Knyaz, C., & Tamura, K. (2018). MEGA X: Molecular

501 Evolutionary Genetics Analysis across Computing Platforms. *Molecular Biology and*

502 *Evolution*, 35, 1547–1549. <https://doi.org/10.1093/molbev/msy096>

503 Lee, J. A., Hwang, M. A., Han, J. H., Cho, E. H., Lee, J. B., Park, S. Y., ... Lee, S. W. (2018).

504 Reduction of mycoplasmal lesions and clinical signs by vaccination against

505 *Mycoplasma hyorhinis*. *Veterinary Immunology and Immunopathology*, 196, 14–17.

506 <https://doi.org/10.1016/j.vetimm.2017.12.001>

507 Lin, J., Chen, S., Yeh, K., & Weng, C. (2006). *Mycoplasma hyorhinis* in Taiwan: Diagnosis

508 and isolation of swine pneumonia pathogen. *Veterinary Microbiology*, 115, 111–116.

509 <https://doi.org/10.1016/j.vetmic.2006.02.004>

510 Martinson, B., Minion, F. C., & Jordan, D. (2018). Development and optimization of a cell-

511 associated challenge model for *Mycoplasma hyorhinis* in 7-week-old cesarean-

512 derived, colostrum-deprived pigs. *The Canadian Journal of Veterinary Research*, 82,

513 12–23.

514 Martinson, B., Minion, F. C., Kroll, J., & Hermann, J. (2017). Age susceptibility of caesarian

515 derived colostrum deprived pigs to *Mycoplasma hyorhinis* challenge. *Veterinary*

516 *Microbiology*, 210, 147–152. <https://doi.org/10.1016/j.vetmic.2017.09.005>

517 Martinson, B., Zoghby, W., Barrett, K., Bryson, L., Christmas, R., Minion, F. C., & Kroll, J.

518 (2018). Efficacy of an inactivated *Mycoplasma hyorhinis* vaccine in pigs. *Vaccine*, 36,

519 408–412. <https://doi.org/10.1016/j.vaccine.2017.11.063>

520 Merodio, M., McDaniel, A., Poonsuk, K., Magtoto, R., Ferreyra, F. S. M., Meiroz-De-Souza-  
521 Almeida, H., ... Derscheid, R. (2021). Evaluation of colonization, variable  
522 lipoprotein-based serological response, and cellular immune response of *Mycoplasma*  
523 *hyorhinis* in experimentally infected swine. *Veterinary Microbiology*, 260, 109162.  
524 <https://doi.org/10.1016/j.vetmic.2021.109162>

525 Morita, T., Fukuda, H., Awakura, T., Shimada, A., Umemura, T., Kazama, S., & Yagihashi,  
526 T. (1995). Demonstration of *Mycoplasma hyorhinis* as a Possible Primary Pathogen  
527 for Porcine Otitis Media. *Veterinary Pathology*, 32, 107–111.  
528 <https://doi.org/10.1177/030098589503200202>

529 Pieters, M. G., & Maes, D. (2019). Mycoplasmosis. In J. J. Zimmerman, L. A. Karriker, A.  
530 Ramirez, K. J. Schwartz, G. W. Stevenson, & J. Zhang (Eds.), *Diseases of Swine* (11th  
531 ed., pp. 863–883). Wiley.

532 R Core Team. (2021). *R: A Language and Environment for Statistical Computing*. Vienna,  
533 Austria: R Foundation for Statistical Computing. Retrieved from <https://www.R-project.org/>

535 Resende, T. P., Pieters, M., & Vannucci, F. A. (2019). Swine conjunctivitis outbreaks  
536 associated with *Mycoplasma hyorhinis*. *Journal of Veterinary Diagnostic  
537 Investigation*, 31, 766–769. <https://doi.org/10.1177/1040638719865767>

538 Roos, L. R., Surendran Nair, M., Rendahl, A. K., & Pieters, M. (2019). *Mycoplasma  
539 hyorhinis* and *Mycoplasma hyosynoviae* dual detection patterns in dams and piglets.  
540 *PLOS ONE*, 14, e0209975. <https://doi.org/10.1371/journal.pone.0209975>

541 Stipkovits, L., Czifra, G., & Sundquist, B. (1993). Indirect ELISA for the detection of a  
542 specific antibody response against *Mycoplasma gallisepticum*. *Avian Pathology*, 22,  
543 481–494. <https://doi.org/10.1080/03079459308418937>

544 Terato, K., Do, C., Chang, J., & Waritani, T. (2016). Preventing further misuse of the ELISA  
545 technique and misinterpretation of serological antibody assay data. *Vaccine*, 34, 4643–  
546 4644. <https://doi.org/10.1016/j.vaccine.2016.08.007>

547 Wang, J., Hua, L., Gan, Y., Yuan, T., Li, L., Yu, Y., ... Xiong, Q. (2022). Virulence and  
548 Inoculation Route Influence the Consequences of *Mycoplasma hyorhinis* Infection in  
549 Bama Miniature Pigs. *Microbiology Spectrum*, 10, e02493-21.  
550 <https://doi.org/10.1128/spectrum.02493-21>

551 Waritani, T., Chang, J., McKinney, B., & Terato, K. (2017). An ELISA protocol to improve  
552 the accuracy and reliability of serological antibody assays. *MethodsX*, 4, 153–165.  
553 <https://doi.org/10.1016/j.mex.2017.03.002>

554 Wei, Y.-W., Zhu, H.-Z., Huang, L.-P., Xia, D.-L., Wu, H.-L., Bian, H.-Q., ... Liu, C.-M.  
555 (2020). Efficacy in pigs of a new inactivated vaccine combining porcine circovirus  
556 type 2 and *Mycoplasma hyorhinis*. *Veterinary Microbiology*, 242, 108588.  
557 <https://doi.org/10.1016/j.vetmic.2020.108588>

558 Wu, Y., Ishag, H. Z. A., Hua, L., Zhang, L., Liu, B., Zhang, Z., ... Xiong, Q. (2019).  
559 Establishment and application of a real-time, duplex PCR method for simultaneous  
560 detection of *Mycoplasma hyopneumoniae* and *Mycoplasma hyorhinis*. *Kafkas Univ*  
561 *Vet Fak Derg*, 25, 405-414. <https://doi.org/10.9775/kvfd.2018.21137>

562

563 **Supplementary information**

564

565 **Supplementary data 1**

566 **Results of the statistical analysis.**

567

568 **Supplementary data 2**

569 **Aligned, concatenated sequences of the multi-locus sequence typing of the challenge strain**  
570 **and the re-isolates.**

571

572 **Supplementary table 1**

573 **Pathological scoring system and detailed pathological scores of necropsy.**

574

575 **Supplementary table 2**

576 **Background information of the strains used in the enzyme-linked immunosorbent assay**  
577 **development.**

578

579 **Supplementary table 3**

580 **Rectal temperatures measured during the study.**

581

582 **Supplementary table 4**

583 **Timescale of appearance of swollen joints.**

584

585 **Supplementary table 5**

586 **Results of weekly weight measurements in kilograms.**

587

588 **Supplementary table 6**

589 ***Mycoplasma hyorhinis* specific PCR results of the nasal samples taken during the study.**

590

591 **Supplementary table 7**

592 ***Mycoplasma hyorhinis* specific PCR results of the samples taken during necropsy.**

593

594 **Supplementary table 8**

595 **Repeat numbers and source of the re-isolates from this study**

596

597 **Supplementary table 9**

598 **Histopathological scores of *Mycoplasma hyorhinis* infected piglets.**

599

600 **Supplementary table 10**

601 **ELISA results of *Mycoplasma hyorhinis* infected piglets.**

602

603 **Supplementary figure 1**

604 **Dendograms of multi locus sequence typing (MLST, A) and multiple-locus variable-  
605 number tandem-repeat analysis (MLVA, B).**

606 A. The MLST tree was constructed by using Maximum Likelihood method, Hasegawa-  
607 Kishino-Yano model in the MegaX software (Kumar, Stecher, Li, Knyaz, & Tamura, 2018).

608 Gene fragments from *lepA*, *rpoB*, *rpoC*, *gltX*, *valS* and *uvrA* were used, with 1000 bootstraps  
609 (only bootstrap values >70% are presented). B. Resolution of the identical sequence type of the  
610 isolates from the present study was carried out with MLVA based on Mhr205, Mhr396,  
611 Mhr438, Mhr441, Mhr442 and Mhr444 alleles. The tree was constructed by Neighbour-Joining  
612 method.

613 Isolates from this study are highlighted light grey on the MLST tree. MLST sequences are  
614 available in Supplementary data 2, and tandem-repeat numbers of the isolates from this study  
615 can be found in Supplementary table 8. Data of the other isolates was previously published in  
616 Földi et al., 2020.